Development of plasmacytoid DC exosomes as new type of cancer vaccines that overcome CDC1 dependence and tumor immunosuppression

Henry Ford Health System received a $620,000 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded September 30, 2025, with a completion date of September 29, 2027. The award funds the development of plasmacytoid dendritic cell (DC) exosomes as a novel cancer vaccine platform designed to overcome CDC1 (conventional dendritic cell type 1) dependence and address tumor immunosuppression. This research initiative will be conducted at the organization's Detroit, Michigan facility.

The project delivers advanced biomedical research and development services focused on transforming cancer immunotherapy through innovative vaccine technology. As a recognized leader in federal medical research partnerships, Henry Ford Health System will conduct hypothesis-driven investigation and translational research activities to develop therapeutic solutions addressing critical cancer treatment challenges. The two-year performance period aligns with typical Military Medical Research and Development program timelines, which emphasize basic and applied research with potential military and public health relevance. This award reflects the DHA's strategic investment in oncology research and immunotherapy innovation through its competitive peer and programmatic review process.